Global Polymerase Chain Reaction Market, by Product Type (Instrument (Real Time PCR, Digital PCR, and Others) and Reagents and Consumables)), by End User (Clinical Diagnostics, Academic and Research Laboratories, Forensic Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5,627.9 Million in 2022 and is expected to exhibit a CAGR of 8.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing advances in polymerase chain reaction technique is expected to drive the market growth over the forecast period. For instance, in October 2021, Thermo Fisher Scientific, the U.S.-based provider of scientific instrumentation, reagents and consumables, launched the applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results in genetic analysis and research within 90 minutes. Digital polymerase chain reaction (dPCR) is a biotechnological refinement of conventional polymerase chain reaction methods that can be used to directly quantify and clonally amplify nucleic acids strands including DNA, cDNA, or RNA.
Global Polymerase Chain Reaction Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global polymerase chain reaction market, owing to increasing launches of new products of polymerase chain reaction technique. For instance, in May 2021, Cipla Limited, an India-based multinational pharmaceutical company, announced the commercialization of a polymerase chain reaction (RT-PCR) test kit 'ViraGen' for COVID-19 in India. The commercialization of the text kit was announced in partnership with Ubio Biotechnology Systems Pvt. Ltd, a biotechnology company. ViraGen is Cipla's third offering in the COVID-19 testing segment.
Global Polymerase Chain Reaction Market: Key Developments
In October 2021, Thermo Fisher Scientific, the U.S.-based provider of scientific instrumentation, reagents and consumables, acquired Combinati, a biotechnology company based in Palo Alto (Palo Alto Networks, Inc. is an American multinational cyber security company) and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of Digital polymerase chain reaction (dPCR)assays. The acquisition ensured QuantStudio Absolute Q Digital PCR System provides solution in biotech and research-academia space.
In April 2022, TATAA Biocenter, Germany-based provider of molecular analysis services announced that it is adding Stilla’s six-color naica system to its digital PCR service offerings. Leveraging on the powerful multiplexing capabilities of the industry’s first digital PCR system featuring six fluorescent channels, TATAA Biocenter will develop custom assays by October 2022, based on TATAA Biocenter’s proprietary Two-Tailed PCR technology and offer ready-to-use dPCR kits for a variety of applications. TATAA Biocenter has proprietary 2T-PCR technology that offers unprecedented specificity when testing for rare sequence variations, which is the most requested analytical service requiring dPCR. With 2T-PCR, much shorter nucleic acids can be tested than with classical PCR, making it the preferred method analyzing forensic samples, formalin fixed and paraffin embedded (FFPE) material, liquid biopsies and ancient DNA, where the nucleic acids may be extensively degraded. The six-color naica system offers the highest multiplexing and detection capacity available on the market and is used by scientists across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing.
Browse 28 Market Data Tables and 34 Figures spread through 150 Pages and in-depth TOC on “Global Polymerase Chain Reaction Market”- Forecast to 2030, Global Polymerase Chain Reaction Market, by Product Type (Instrument (Real Time PCR, Digital PCR, and Others) and Reagents and Consumables)), by End User (Clinical Diagnostics, Academic and Research Laboratories, Forensic Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights related to polymerase chain reaction market, click the link below:
https://www.coherentmarketinsights.com/market-insight/polymerase-chain-reaction-market-1546
Key Takeaways of the Global Polymerase Chain Reaction Market:
- The global polymerase chain reaction market is expected to exhibit a CAGR of 8.9% during the forecast period due to the increasing adoption of inorganic growth strategies such as merger and acquisition by the key players in the market for developing rapid identification of bloodstream infections and the detection of antimicrobial resistance genes. For instance, in May 2021, F. Hoffmann-La Roche AG, commonly known as Roche, multinational healthcare company acquired GenMark Diagnostics to expand its portfolio of molecular diagnostics with GenMark’s expertise in syndromic testing. The companies believe that GenMark’s ePlex systems will enhance Roche’s work in managing infectious diseases and antibiotic resistance. The ePlex platform is designed to detect multiple pathogens from a single rapid test and a patient sample, allowing clinicians to determine a cause of infection and prescribe treatment within hours. Roche and GenMark Diagnostics have entered into a merger agreement in which Roche acquired GenMark for $1.8 billion. GenMark’s offerings will complement Roche’s portfolio of COVID-19 diagnostic solutions, as Roche will gain access to GenMark’s Respiratory Pathogen Panels, which identify the most common viral and bacterial organisms associated with upper respiratory infection, including SARS-CoV-2.
- Reagents and consumables hold major market share in product type segment, owing to its inevitable need in PCR instruments to run the sample and amplify the target DNA sequence.
- Among regions, North America is estimated to account for the largest market share in the global polymerase chain reaction market over the forecast period, owing to the increasing launches of new technologies in that region. For instance, in June 2022, Bio-Rad Laboratories, Inc., a U.S.-based developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets launched CFX Duet Real-Time PCR System to help researchers develop singleplex and duplex quantitative polymerase chain reaction assays. Bio-Rad Laboratories Inc., developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets announced the launch of the CFX Duet Real-Time PCR System on May 26, 2022. The CFX Duet is designed to help researchers develop singleplex and duplex quantitative polymerase chain reaction (qPCR) assays.
- Major players operating in the global polymerase chain reaction market include F.Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation.
